GlassScriptPhysician profile
Danielle M Neff
NPI 1184390536
$848.73
in general payments reported to CMS, 2019-2025
13 companies · $368 in 2025
The $368 reported for 2025 was more than what 79% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.34 · 2023: $293 · 2024: $176 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $291.41 | 2023-2025 | |
| Astellas Pharma US INC | $96.64 | 2023-2024 | Veozah |
| Mayne Pharma Commercial LLC | $96.45 | 2024-2025 | |
| Organon LLC | $79.96 | 2021-2025 | Nexplanon |
| Millicent US INC | $53.95 | 2025 | Intrarosa, Femlyv, Femring |
| Exact Sciences Corporation | $50.62 | 2024-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $44.57 | 2025 | Myfembree, Gemtesa |
| Pfizer INC. | $35.03 | 2024-2025 | |
| Sage Therapeutics, LLC | $24.48 | 2025 | Zurzuvae |
| Daiichi Sankyo INC. | $24.08 | 2025 | Injectafer |
| Aspira Women'S Health INC | $22.37 | 2025 | Ova1 |
| Amgen INC. | $14.73 | 2025 | Evenity |
| Shield Therapeutics INC | $14.44 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Neff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.